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eek and Treat Obstructive
leep Apnea in Heart Failure*
hierry H. Le Jemtel, MD,†
anja Jelic, MD‡
ew Orleans, Louisiana; and New York, New York
bstructive sleep apnea (OSA) is a highly prevalent disor-
er. It affects 9% to 25% of the North American population
1–4). Intermittent cessation of breathing during sleep
aused by occlusion of the upper airway followed by arousals
rom sleep defines OSA. The prevalence of OSA is even
reater among patients with chronic heart failure (CHF).
pproximately one-third to one-half of the 5 million
mericans with CHF suffers from concomitant OSA,
specially those with severe CHF (5–7). Notwithstanding
he sheer number of patients with OSA and obesity as a
ommon risk factor, repetitive episodes of hypoxia/
eoxygenation, augmented intrathoracic pressure swings,
nd arousals from sleep promote arterial stiffness, hyperten-
ion, and increased sympathetic activity that account for the
requent coexistence of OSA and CHF (8–10). Patients
ith OSA are 2.2 times more likely to develop CHF than
atients without OSA, and patients with CHF who develop
SA are thought to have a worse prognosis than patients
ith CHF alone (11).
See page 1625
In this issue of the Journal, Wang et al. (12) report their
xperience in the context of a single-center prospective
bservational study that compared the mortality of patients
ith coexistent CHF and OSA with that of patients with
nly CHF over an average period of 33 months. The
ortality of patients with CHF and untreated OSA was
early 2-fold greater than that of patients with CHF alone.
n contrast, none of the patients with CHF and treated
SA died during the 39-month follow-up period.
These findings, although not unexpected and somewhat
ptimistic, are of great importance. Treatment with contin-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Section of Cardiology, Tulane University School of Medicine, New
rleans, Louisiana; and the ‡Division of Pulmonary, Allergy, and Critical Careu
edicine, Columbia University College of Physicians and Surgeons, New York,
ew York.ous positive airway pressure (CPAP) for 4 h per night does
ot improve survival in patients with CHF and central sleep
pnea (CSA) (13). However, in contrast to CSA that is a
onsequence of CHF, OSA is on its own a risk factor for
ypertension and stroke and is likely to impact negatively on
eft ventricular function (9,14). Patients with untreated
evere OSA have a higher incidence of fatal cardiovascular
vents (1.06 vs. 0.35 per 100 person-years, p  0.0008) and
onfatal cardiovascular events (2.13 vs. 0.64 per 100 person-
ears, p  0.0001) than patients treated with CPAP after
djustment for pre-existing cardiovascular risk factors (15).
The observation by Wang et al. (12) that untreated OSA
ndependently increases mortality in CHF is important
ecause OSA remains frequently unrecognized in patients
ith CHF (7). The modest impact of OSA on subjective
easurements of sleepiness or quality of life may explain
hy OSA is so often unrecognized in patients with CHF
16). To make things worse, even when recognized OSA
emains often untreated, as was the case in the report by
ang et al. (12). Hopefully the positive findings in their
eport will encourage physicians and nurse practitioners who
are for patients with CHF to be more vigilant about the
iagnosis and treatment of OSA.
Wang et al. (12) contend that treatment with CPAP
egates OSA-related increase in mortality in patients with
HF, but they do not definitively prove it. Patients with
HF and OSA were not randomly assigned to CPAP.
oreover, the majority of patients were not treated with
PAP for unclear reasons. Patients with CHF who are
illing to comply with CPAP treatment may be more
ealth conscious and thus more adherent to other treatment
odalities and more likely to do well.
Treatment with CPAP has become the standard of care
or moderate to severe OSA, and thus unbiased random-
zation of OSA patients to CPAP or no CPAP may no
onger be feasible (17). Confronted with evidence that
upports the use of CPAP in the management of OSA,
hysicians may not be willing to enroll patients with severe
SA into a randomized trial, thereby biasing the trial
oward negative results. The use of a multivariate risk model
o predict 1-, 2-, and 3-year mortality of patients with
oexistent CHF and OSA who have accepted or refused
reatment with CPAP may be a preferable and ethical
pproach for evaluating the effects of CPAP on clinical
utcomes in this patient population (18).
Objective evaluation of the minimum CPAP adherence
eeded for reduction of mortality is also a worthwhile goal
n patients with OSA and CHF. Wang et al. (12) reported
PAP adherence as self-reported “use” or “no use.” Subjec-
ive or objective CPAP adherence data were not provided.
elf reporting of CPAP adherence is notably unreliable
19). In a prospective study that covertly monitored objec-
ive CPAP adherence, 60% of patients claimed to use
PAP nightly; however, only 46% met criteria for regular
se, and they overestimated CPAP use by more than 1 h
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April 17, 2007:1632–3 Editorial Comment16). In the report by Wang et al. (12), the majority of
atients with coexistent OSA and CHF did not receive
PAP treatment because they were not complaining of
aytime sleepiness. Patients with moderate to severe OSA
ocumented by nocturnal polysomnography should not be
eft untreated (17). One to three months of CPAP treat-
ent increases left ventricular ejection fraction and im-
roves quality of life in patients with coexistent CHF and
SA whether or not they complain of daytime sleepiness
20,21).
Lastly, CPAP therapy may not completely reverse the
omplications associated with OSA. Many patients with
SA continue to experience daytime sleepiness despite
ffective long-term CPAP therapy (22). Reduction of oxi-
ative stress requires effective CPAP therapy for at least 3
onths, whereas antioxidant defense remains partially im-
aired after 12 months of therapy in OSA patients (22–25).
dherence to treatment is hampered by the cumbersome-
ess of CPAP devices, and proper delivery of pressures is
requently impaired by ill-fitting facial interfaces and inad-
ertent leaks. Delayed diagnosis and poor adherence to
PAP treatment may contribute to the partial reversibility
f OSA cardiovascular manifestations. Nevertheless, as
bserved in the study by Wang et al. (12), effective CPAP
herapy may halt progression of the underlying cardiovas-
ular condition. Therefore, early diagnosis of OSA and
nitiation of effective CPAP therapy are of paramount
mportance in patients with coexistent CHF and OSA.
uture studies will establish the minimum duration of
ightly CPAP therapy needed to offset the impact of OSA
n morbidity and mortality in CHF.
In summary, the observational study by Wang et al. (12)
oints out the therapeutic usefulness of CPAP in patients
ith coexistent CHF and OSA. The findings of this
bservational study need to be confirmed by either a large
andomized trial or a detailed registry of the use or lack of
se of CPAP in patients with coexistent CHF and OSA.
he latter approach seems preferable for ethical and prac-
ical reasons.
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